LQDA VS LUNG Stock Comparison

Performance

LQDA
100/100

LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.

LUNG
10/100

LUNG returned 65.89% in the last 12 months. Based on SPY's performance of 440.50%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

LQDA
88/100

4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.

LUNG

"Analyst Price Targets" not found for LUNG

Sentiment

LQDA
68/100

LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.

LUNG
84/100

LUNG had a bullish sentiment score of 84.35% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.

Technicals

LQDA
29/100

LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

LUNG
64/100

LUNG receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

LQDA
10/100

LQDA has missed earnings 11 times in the last 20 quarters.

LUNG
100/100

LUNG has missed earnings 1 times in the last 20 quarters.

Profit

LQDA
10/100

Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

LUNG
10/100

Out of the last 17 quarters, LUNG has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

LQDA
48/100

LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

LUNG
54/100

LUNG has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Liquidia Corporation Common Stock Summary

Nasdaq / LQDA

Healthcare

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Pulmonx Corporation Common Stock Summary

Nasdaq / LUNG

Healthcare

Medical - Devices

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Power up your portfolio